Statewide Support of Thrombocytopenic Patients with ABO Matched Single Donor Platelets

Publisher Website
Google Scholar
Abstract
Use of ABO matched, HL-A nonmatched platelet units obtained from single donors by pheresis, using the Hemonetics 30 Cell Separator, has a lowered hepatitis risk, and possibly delays the onset of the refractory state. Pheresis also offers a method of obtaining HL-A matched platelets for the already refractory patient. A mean of 4.2 .times. 1011 platelets are collected in about 1 1/2 h. ABO matched, HL-A nonmatched platelets produced corrected increments of more than 2500/mm3 per 7 .times. 1010 platelets infused in 67% of transfusions to nonselected recipients. The procedure is simple, safe and requires little time. It is a worthwhile large-scale program for a regional blood center to undertake in providing optimal therapy for thrombocytopenic patients.